
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Feline infectious peritonitis
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Read
Amongst the many feline viruses, the agent that causes FIP is perhaps the most elusive and frustrating to diagnose and treat. Elizabeth Berliner offers a review of the disease and some pointers as to what may be around the corner in terms of therapy.
Elizabeth A. Berliner
DVM, Dipl. ABVP
Dr. Berliner earned her DVM from Cornell University in 2003 and is boarded in both Shelter Medicine Practice (2016) and Canine and Feline Practice (2012) with the American Board of Veterinary Practitioners. She is currently Assistant Clinical Professor and Director of Maddie’s® Shelter Medicine Program at Cornell University and serves on the Board of Directors for the Association of Shelter Veterinarians and the credentials committee for the Shelter Medicine Practice board specialty. Her interests include diagnosis, management and prevention of infectious diseases; animal welfare, veterinary ethics, and decision-making; and innovative outreach programs promoting accessible veterinary care and humane behaviors.

Key Points
- Feline Infectious Peritonitis (FIP) is the result of a mutation of the ubiquitous feline coronavirus (FCoV).
- Risk factors for FIP include cats less than 2 years of age, group housing, and exposure to stressful events, including surgery or rehoming.
- Diagnosis is often complicated and relies on a combination of history and clinical signs supported by diagnostic testing; FCoV serology should never be used to make a diagnosis of FIP.
- FIP usually shows rapid progression of clinical signs and is generally terminal. Treatment is typically unrewarding, but there are currently some promising experimental therapies under investigation. ...
Introduction
Feline Infectious Peritonitis (FIP) is the result of a mutation of the ubiquitous and relatively harmless feline coronavirus (FCoV). First described in 1963 ( 1 ), the rise and increased incidence of FIP since its discovery has been associated with husbandry practices that result in group-housed cats; this includes breeding and sheltering facilities. The first commercial cat litter appeared on the US market in 1947 ( 2 ) — a reflection of the changing role of the cat as an indoor companion animal — and both breeding and rescue operations increased in the following decades, creating opportunities for transmission and amplification of infectious diseases in groups of cats. To date, FIP has evaded medical prevention modalities as well as a cure; furthermore, ante-mortem diagnosis often remains a clinical challenge. Current research includes enhanced diagnostic tools utilizing molecular sequencing and clinical trials of new therapies; both of these areas suggest promising advances in the field.
Etiology and pathogenesis
Feline coronavirus is a large, enveloped, positive-stranded RNA virus. Coronaviruses in general exhibit a high rate of mutation during replication, which leads to intra-species and cross-species recombination and transmission. Currently, FCoV is considered to have two serotypes: type I, which is the most prevalent form found worldwide in naturally affected cats (with some geographic variation), and type II, which arose from a recombination event between type I FCoV and canine coronavirus. Although type 1 predominates in natural feline infections, the vast majority of research has been conducted on type II because it is more readily propagated in the laboratory for study. Both type I and type II FCoV serotypes have been implicated in FIP development ( 3 ). Type I and type II are distinguished by genetic differences in their S (spike) proteins (Figure 1), which are considered important in the transformation of common FCoVs to the FIP-causing FCoVs (FIPVs).

Figure 1. A schematic image of the FCoV viral antigen. Spike (S), membrane (M), and envelope (E) proteins are anchored in a bi-lipid membrane. S and M proteins are important in gaining entry into cells, and current research suggests point mutations in the S gene play a role in transformation from FCoV to FIPV.
The main route of FCoV transmission is fecal-oral, with oronasal inoculation of the virus via direct transmission or fomites such as litterboxes or surfaces. After inoculation, FCoV moves into intestinal enterocytes, where the virus replicates. Infections with FCoV are often subclinical, but may result in a self-limiting diarrhea as the virus impacts the intestinal epithelium.
The transformation of the common FCoV to the lethal FIPV involves specific point mutations in the RNA genome. Structural features of interest are the viral spike (S) and membrane (M) proteins which act in allowing entry into and exit from cells (Figure 1). An understanding of specific point mutations is thought to be the key in unlocking this lethal transformation; current efforts are focused primarily on the S and 3c genes, with the S gene being most commonly implicated in laboratory studies to date ( 4 ).
The macrophage is the primary inflammatory cell in FIP. Point mutations in the FCoV genome switch the virus from an epithelial tropism to a macrophage trophism. The resulting virus is then able to travel and replicate in macrophages, moving into organs and other tissues. Infected macrophages internalize antigen, allowing the virus to evade antibody-dependent lysis, while also activating complement which increases the influx of other inflammatory cells to infected tissues. The humoral branch of the immune response is also activated, resulting in the deposition of antibody-antigen complexes along vessels, causing profound and widespread vasculitis. Approximately 50% of FIP cases develop effusive disease, while the other 50% develop the less-effusive granulomatous presentation; however, the classic dichotomy is a false one, as the disease acts along a spectrum between effusive and non-effusive signs. This variation is theorized to depend on which branch of the immune system is most active in responding: the humoral system results in more effusive disease, and the complement system in the more granulomatous presentation ( 5 ). [...]
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
About
How to reference this publication (Harvard system)?
Author(s)
Copyright Statement
© All text and images in this publication are copyright protected and cannot be reproduced or copied in any way.Related Content
Readers also viewed these publications
Subscribe
Access to the content of the Veterinary Focus website is reserved for animal health professionals. If you do not yet have a user account with Royal Canin you can create a free account by selecting the New User form. Subscription to the journal is free and issues in your preferred language can be obtained at the Veterinary Focus website.

Comments (0)
Ask the author
0 comments